Cellmid Ltd., of Sydney, Australia, said it signed an agreement with Zoetis Inc., of Madison, N.J., for the evaluation and option to license one of Cellmid's anti-midkine antibodies (MK antibody) for therapeutic use in companion animals. Their MK antibodies previously have been shown to be effective in animal models of a number of diseases. The terms of the agreement include up-front and exclusivity payments until the option to license potentially exercised. Additional financial details were not disclosed.